SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (1114)3/22/2000 11:59:00 AM
From: Ron  Read Replies (1) of 1386
 
Rick, thank you for the reply. Certainly, I was not attempting to be misleading. I am aware of the fact that the cohort treated with HU-211 had more severe head trauma. I was wondering, since the release says "the trend for better neurological outcome" in phase 2/3 was not the same as the first two cohorts, if that had a overall negative impact on phase 2/3?

trend for better neurological outcome in
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News